Assistant Professor; Director, Brain Tumor Biology and Therapy Lab
University of Pittsburgh
Sameer Agnihotri, PhD, joined the faculty of the Department of Neurological Surgery at UPMC Children’s Hospital of Pittsburgh in November of 2016.
Dr. Agnihotri graduated from the University of Toronto in 2005 with a bachelor of science honors degree in biology, specializing in genetics. He earned his PhD in medical biophysics in 2011 from the University of Toronto where he used genetic screens to identify novel drivers of glioblastoma, an incurable brain tumor. He subsequently completed his post-doctoral fellowship at the Arthur and Sonia Labatt Brain Tumor Research Centre at the Hospital for Sick Children, in Toronto, and the Princess Margaret Cancer Centre, Division of Neuro-oncology Research, also in Toronto.
Integrated Genomic Analysis to elucidate the role of PIKC3A and 10q LOH as Unique drivers and cooperating events in pediatric high grade gliomas
We have previously reported a high frequency of AKT activation, a downstream target of PTEN, in pediatric high-grade gliomas (pHGGs), as assessed by immunohistochemistry (IHC), and demonstrated that this was associated with an adverse prognosis. Compared to adult high-grade gliomas, pHGGs show a
Elucidating the Somatic Epigenetic Landscape of Pediatric Meningioma and Schwannoma
Meningioma and schwannoma are intracranial nervous system tumors that are predominantly benign in behavior arise through mutation and loss of function in the Neurofibromatosis type 2 (NF2) gene. Meningioma is the most common primary brain tumor and has a variable risk of local recurrence.O
High-grade glioma/astrocytoma (WHO grade III/IV)
High-grade Gliomas (HGG) in children nearly always result in a dismal prognosis. Although novel therapeutic approaches are currently in development, preclinical testing has been limited, due to a lack of pediatric specific HGG preclinical models. These models are needed to help test the effective
Brainstem glioma- Diffuse intrinsic pontine glioma
A presumptive diagnosis of DIPG based on classic imaging features, in the absence of a histologic diagnosis, has been routinely employed. Increasingly however, histologic confirmation is obtained for both entry into research studies and molecular characterization of the tumor.[